MTAP Technologies Pvt. Ltd., a leading provider of cloud-native SaaS solutions transforming transportation management and ...
"This study establishes MTAP-del as a biomarker in bladder cancer. We are now ready for a trial in MTAP-del bladder cancer in combination with other inhibitors of the pathway." --Joaquim Bellmunt, MD, ...
“In breast cancer, MTAP downregulation activates ornithine decarboxylase (ODC) which in turn leads to formation of putrescine which promotes tumor migration, invasion and angiogenesis [15].” “We ...
First-in-human phase I/II study of BYS10 in patients (pts) with locally advanced or metastatic RET-altered solid tumors: Preliminary dose escalation results.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results